Five-member board brings hands-on leadership in biomaterials commercialization, medical technology, spine innovation, OEM ...
DiFusion recently completed a series of in vivo and in vitro clinical tests. These tests were performed by third party institutions whereby the results showed CleanFUZE™ eradicated 99.998% of ...
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- DiFusion Therapeutic Biomaterials today announced that it will use the ...
AUSTIN, Texas, Jan. 14, 2025 /PRNewswire/ -- DiFusion Technologies, an industry leader in advanced biomaterials for surgical implants, announced today the issuance of a new US Patent 12,178,936 B2 ...
AUSTIN, Texas, Oct. 7 /PRNewswire/ -- DiFUSION Technologies is a medical device company focused on the development and commercialization of its proprietary CleanFUZE™ antimicrobial technology for ...
AUSTIN, Texas--(BUSINESS WIRE)--DiFusion Technologies, maker of the ZFUZE™ suite of surgical polymers, today announced the addition of Todd Potokar to its Board of Directors. In addition, Rich Grant ...
AUSTIN, Texas--(BUSINESS WIRE)--DiFusion Technologies, Inc. today announced promising data for the company’s ZFUZE Immuno-Stealth™ Surgical Polymer. The data and the importance of the immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results